Skip to main content
Premium Trial:

Request an Annual Quote

DNAVision to Use Roche s AmpliChip CYP450 Test

NEW YORK, Nov. 3 (GenomeWeb News) - DNAVision will begin service of Roche Diagnostics' AmpliChip CYP450 test, the company said today.


The AmpliChip CYP450, which is built upon the Affymetrix microarray platform, analyzes the cytochrome P450 2D6 and 2C19 genotypes to help determine the appropriate dosages of medications for a variety of conditions, including pain medication, cardiac disease, cancer, and depression.


"DNAVision is proud to be chosen by Roche Diagnostics Belgium as the first European pharmacogenomic private testing laboratory to provide this first FDA approved DNA microarray test" said Arnaud Termonia, scientific advisor of DNAVision, in a statement.


The U.S. Food and Drug Administration cleared the AmpliChip CYP450 test for diagnostic use earlier this year.





The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.